
Help Your Patients Maintain Tighter Control
-
Longer wear time
92% industry-leading adherence across 3 pivotal trials.1-3
Fully implantable 180-day sensor.
Continuous readings and alerts around the clock.
Greater insight
Exceptional accuracy, especially in the 2.2-3.3 mmol/L range.1
Charts, graphs and in-app reports to improve glycemic awareness.
Three types of alerts (audio, on body vibe and mobile text) to guide safe management.
Fewer obstacles
No twice-monthly sensor replacement.
Near-real time feedback to help predict and monitor trends.
Detects 95% of hyper/hypo events in 15 minutes.1
Improved self-management
Exceptional 59-69% real-world time in target.1
Sign Up Your Patients Today
The Eversense XL long-term CGM System uniquely balances accuracy and discretion with an exceptional user experience.
1 Christiansen MP. PRECISION. Diabetes Technology & Therapeutics. Volume 21, Number 5, 2019. 2 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 3 Kropff J, Choudhary P, Neupane S, et al. PRECISE. Diabetes Care. 2017;40(1):63-68. 4 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 5 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
MKT-001284 Rev1